Phanes Therapeutics announces clinical supply agreement with BeiGene

Phanes Therapeutics announced a clinical supply agreement with BeiGene to evaluate the safety and efficacy of Phanes’ PT199, a differentiated anti-CD73 monoclonal antibody in combination with BeiGene’s tislelizumab, an anti-PD-1 monoclonal antibody in the Phase I clinical study for the treatment of multiple advanced solid tumors. "We are excited about the opportunity to evaluate PT199 in combination with tislelizumab for the treatment of solid tumors. PT199 is an anti-CD73 monoclonal antibody with a differentiated mechanism of action to counter the immunosuppressive tumor microenvironment in cancer patients. The combination of PT199 with tislelizumab provides a new opportunity to assess the strategy to enhance antitumor immune response in patients with advanced or metastatic cancer refractory to previous treatments," said Dr. Ming Wang, Founder and CEO of Phanes.